Caplin Point FY22 Annual report highlights
FY 16 topline has become FY22 Bottom line. FY16 Topline 243 FY 22 Bottom-line – 308Cr
Operations target:
To backward integrate to KSM for 70% of US Products by FY24 to reduce costs.
Caplin Steriles has completed Pre mixed bags line, Filing will start in the US by Q4 FY23.
Capex
Invested over 355Cr in the last 5Years.
Will invest 500-560Cr Moving forward
300Cr in Expansion and maintenance
130Cr Oncology
100r API
Total R&D Spend(Capex+Opex) Stood at 20% of FY22 PAT.
Branded Generic Revenue share increased from 5% to 25% over FY12 and FY22.
African revenue doubled over 4years and focused mainly on branded generic products in Africa.
Asset light model where 55% of production is outsourced.
LATAM business:
In line to open its own distribution in Chile.
Filed 13 registrations in Mexico and 2 approved
44 Filed in Peru and approved 29
75 Registration in Chile and further 20 More in pipeline.
Have opened 33 retail chains and plan to take in to 50 by 2022 and in 2023 plan to launch a franchise model.
Online B2B Platform has grown 30%(trying to get exact numbers).
Caplin Steriles
75% is Own Products and 25% is CMO(contract manufacturing) for large players
API for caplin steriles will be organic and will come up in 18 Months.( previously they were planning to acquire API Plant in Vizag)
Expanding Caplin steriles 3 new lines, out of this 2 will be under a new unit and said new unit will have
provision to accommodate 4 more lines depending upon the demand in future.
Receivable Days and Inventory days
As company has entered tender business mostly government contracts thus having a longer receivable days and company has ventured into aggressive growth the where credit has to be given in terms of sales (previously an advance will be collected from customers and product will be supplied now this has changed) both of these factors were the reason the negative working capital has been changed.
Inventory days
The company has acquired and in process of acquiring its channel partners thus resulting in increasing the inventory days. Previously consignments in transit were considered as goods sold to channel partners thus reducing the inventory, since the company has acquired the channel partners only when the actual sales happen the inventory will be reduced.
However the company has maintained its inventory days significantly well below its peers and maintaining the receivable days/debtor days with its peers
Guidelines
20% Growth
30%+ Margins.
FY 22 topline will be FY 28 bottom Line – FY22 Topline 1300 CR
Will be under TOP 30 Indian Pharma Companies.
The Guideline is quite ambitious, the countries in which the companies operate currently have a combined population size of Tamil Nadu and they are entering Brazil and Mexico which have very large markets and expanding to other countries like Chile and Peru. Thus giving a revenue opportunity and entering regulated markets US & Canada etc.
Strategic partners: Eight road and F-Prime(A fund whose primary focus is Healthcare and technology) into Steriles gives more conviction.
2026 Guidance- LATAM Business revenue will double(LATAM & Africa revenue 1170 IN FY22) and Steriles will be 100 Million dollar (800CR REVENUE) Currently 130Cr. – Interview by COO Will double our topline in next 5 years: Caplin Point – YouTube
Disclosure: Invested
| Subscribe To Our Free Newsletter |
